These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2388639)

  • 21. [Piracetam in the treatment of soft tissue rheumatism].
    Glas-Schöttl R
    Fortschr Med; 1989 Apr; 107(13):298-302. PubMed ID: 2656442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Piracetam in the modern pharmacotherapy of the Parkinson syndrome].
    Med Welt; 1978 Sep; 29(35):1381-8. PubMed ID: 682917
    [No Abstract]   [Full Text] [Related]  

  • 25. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of piracetam in cortical myoclonus.
    Brown P; Steiger MJ; Thompson PD; Rothwell JC; Day BL; Salama M; Waegemans T; Marsden CD
    Mov Disord; 1993; 8(1):63-8. PubMed ID: 8419809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, placebo-controlled study of piracetam in elderly psychiatric patients [proceedings].
    Chouinard G; Annable L; Ross-Chouinard A; Olivier M; Fontaine F
    Psychopharmacol Bull; 1981 Jan; 17(1):129. PubMed ID: 7232645
    [No Abstract]   [Full Text] [Related]  

  • 32. A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
    De Michele G; Mengano A; Filla A; Trombetta L; Campanella G
    Acta Neurol (Napoli); 1989 Dec; 11(6):408-14. PubMed ID: 2694799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
    Gallai V; Mazzotta G; Del Gatto F; Montesi S; Mazzetti A; Dominici P; Della Monica A
    Acta Neurol (Napoli); 1991 Feb; 13(1):1-12. PubMed ID: 1867125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
    Grundmann M; Schimrigk K
    J Neural Transm Suppl; 1987; 25():115-9. PubMed ID: 3323420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind investigation of piracetam (nootropil) versus placebo in the memory of geriatric inpatients.
    Abuzzahab FS; Merwin GE; Zimmermann RL; Sherman MC
    Psychopharmacol Bull; 1978 Jan; 14(1):23-5. PubMed ID: 343146
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of piracetam on the brain-organic psychosyndrome in cerebrovascular insufficiency. Results of a double-blind study in 40 cases].
    Trabant R; Poljakovic Z; Trabant D
    Ther Ggw; 1977 Aug; 116(8):1504-21. PubMed ID: 331549
    [No Abstract]   [Full Text] [Related]  

  • 37. Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
    Gainotti G; Nocentini U; Sena E
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S47-59. PubMed ID: 2694229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piracetam in chronic brain failure.
    Lloyd-Evans S; Brocklehurst JC; Palmer MK
    Curr Med Res Opin; 1979; 6(5):351-7. PubMed ID: 540525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High versus low-dose piracetam in alcohol organic mental disorder: a placebo controlled study.
    Barnas C; Miller C; Ehrmann H; Schett P; Günther V; Fleischhacker WW
    Psychopharmacology (Berl); 1990; 100(3):361-5. PubMed ID: 2179979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The efficacy of Piracetam on the mental functional capacity of chronic alcoholics (author's transl)].
    Binder S; Doddabela P
    Med Klin; 1976 Apr; 71(17):711-6. PubMed ID: 775275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.